SLN, NLC, LDC: State of the art in drug and active delivery

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 3, 2011, Pages 178-187

  Attama, Anthony A ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Applications in drug delivery; Lipid drug conjugate nanoparticles; Nanostructured lipid carriers; Patents; Solid lipid nanoparticles

Indexed keywords

CHLORAMPHENICOL; CISPLATIN; DICLOFENAC; DRUG CARRIER; HYDROCORTISONE; IMMUNOLOGICAL ADJUVANT; INSULIN; ITRACONAZOLE; LEUPRORELIN; LIPID DRUG CONJUGATE NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; OFLOXACIN; PSORALEN; SOLID LIPID NANOPARTICLE; STEARIC ACID; TACROLIMUS; TIMOLOL; UBIDECARENONE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BIOAVAILABILITY; BODY TEMPERATURE; CRYOELECTRON MICROSCOPY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; ELASTICITY; EMULSION; HYDRATION; HYDROPHILICITY; HYDROPHOBICITY; INTERNALIZATION; LIGHT SCATTERING; LIPOPHILICITY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATENT; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RETICULOENDOTHELIAL SYSTEM; SCANNING TRANSMISSION ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SUPERCRITICAL FLUID EXTRACTION;

ANIMALS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; NANOMEDICINE; NANOSTRUCTURES; PATENTS AS TOPIC; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052863988     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221111797200524     Document Type: Article

References (101)

1. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25: 103-28.
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986; 6: 193-210.
3. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissue. Jpn J Can Res 1998; 89: 307-14.
4. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
5. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169-85.
6. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul 2001; 41: 189-207.
7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Rel 2000; 65: 271-84.
8. Arnaud B, Saulniera P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-67.
9. Byrne JD, Betancourt T, Peppas LB. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60: 1615-26.
10. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 30,50-dioctanoyl-5-fluoro-20-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002; 54: 285-90.
11. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Rel 2008; 127: 97-109.
12. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59: 454-77.
13. Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K. Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Rel 2009; 137: 69-77.
14. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504
15. Muller RH, Lippacher A, Gohla, S. In: Wise D Ed. Handbook of Pharmaceutical Controlled Release Technology. Marcel Dekker: New York 2000: 377-91.
16. Souto EB, Muller RH. In: Thassu D, Deleers M, Pathak Y, Eds. Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. CRC Press: Bocca Raton 2007: 213-33.
17. Muller RH, Mehnert W, Souto EB. In: Bronaugh L Ed., Percutaneous Absorption. Marcel Dekker: New York 2005: 719-38.
18. Xie SY, Wang SL, Zhao BK, Han C, Wang M, Zhou WZ. Effect of PLGA as a polymeric emulsifer on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces 2008; 67: 199-204.
19. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-96.
20. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
21. Zhang ZW, Bu HH, Gao ZW, Huang Y, Gao F, Li YP. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm 2010; 394: 147-53.
22. ®) versus drug nanocrystals. Int J Pharm 2006; 317: 82-9.
23. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Maeder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Rel 2004; 95: 217-27.
24. Freitas C, Muller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN (TM)) dispersions. Int J Pharm 1998; 168: 221-9.
25. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-8.
26. Müller, R.H., Souto, E.B., Radtke, M. Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates. EP0004111 (2000).
27. Muller, R.H., Mader, K., Lippacher, A. Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same. WO0067728 (2000).
28. Radtke M, Souto EB, Müller RH. Nanostructured lipid carriers. Pharm Tech Eur 2005; 17(4): 45-50.
29. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-191.
30. Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin Drug Deliv 2009; 6(2): 165-76.
31. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131-55.
32. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J Control Rel 1994; 30: 83-96.
33. Olbrich C, Mueller RH, Kayser O. Lipid drug conjugate nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazene aceturate. J Drug Target 2002; 10(5): 387-96.
34. Muller, R.H. Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates. WO0067800 (2000).
35. Müller, R.H., Luck, S.J.S. Arzneistoffträger aus festen Lipidteilchen-Feste lipid nanosphären (SLN). EP0605497 (1996).
36. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. US5250236 (1993).
37. Carlotti ME, Sapino S, Trotta M, Battaglia L, Vione D, Pelizzetti E. Photostability and stability over time of retinyl palmitate in an o/w emulsion and in SLN Introduced in the emulsion. J Disper Sci Technol 2005; 26: 125-38.
38. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007; 6: 444-53.
39. Gallarate M, Trotta M, Battaglia L, Chirio D. Cisplatin-loaded SLN produced by coacervation technique. J Drug Deliv Sci Tech 2010; 20(5): 343-47.
40. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencapsul 2010; 27(1): 78-85.
41. Gallarate M, Battaglia M, Peira E, Trotta M. Peptide-loaded solid lipid nanoparticles prepared through coacervation technique. Int J Chem Engin 2011; doi:10.1155/2011/132435.
42. Battaglia, L.S., Trotta, M., Cavalli, R. Method for the preparation of solid lipid micro and nanoparticles. WO2008149215 (2008).
43. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, Peng X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 2011; 6: 683-92.
44. Fricker G, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert R-O, Martin F, Müller-Goymann C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010; 27: 1469-86.
45. Zhang X, Pan W, Gan L, Zhu C, Gan Y, Nie S. Preparation of a dispersible PEGylate nanostructured lLipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem Pharm Bull 2008; 56(12): 1645-50.
46. Hu F-Q, Jiang S-P, Du Y-Z, Yuan H, Ye Y-Q, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids and Surfaces B: Biointerfaces 2005; 45: 167-73.
47. Olbrich C, Gessner A, Schroeder W, Kayser O, Müller RH. Lipiddrug conjugate nanoparticles of the hydrophilic drug diminazenecytotoxicity testing and mouse serum adsorption. J Control Rel 2004; 96: 425-35.
48. Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration, Eur J Pharm Biopharm 2004; 58: 343-56.
49. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993; 89: R9-R12.
50. Olbrich C, Gebner A, Kayser O, Muller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazene diaceturate. J Drug Target 2002; 10: 387-96.
51. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically-complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004; 93: 1993-2004.
52. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug resistant human breast cancer cells. Pharm Res 2006; 23: 1574-85.
53. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymerlipid hybrid nanoparticle (PLN) system. J Pharmacol Exp Ther 2006; 317: 1372-81.
54. Li Y, Taulier N, Rauth AM, Wu XY. Screening of lipid carriers and characterization of drug-polymer complex for the rational design of polymer-lipid hybrid nanoparticles. Pharm Res 2006; 23: 1877-87.
55. Edwards KA, Baeumner AJ. Analysis of liposomes. Talanta 2006; 68: 1432-41.
56. Crawford R, Dogdas B, Keough E, Haas RM, Wepukhulu W, Krotzer S, Burke PA, Laura Sepp-Lorenzino, Ansuman Bagchi, Bonnie J. Howell, Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. Int J Pharm 2011; 403: 237-44.
57. Müller, R.H., Lück, M., Kreuter, J. Medicament excipient particles for tissue specific application of a medicament. WO9920256 (1997)
58. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Rel 1997; 48: 223-36.
59. Jenning V, Thunemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000; 199: 167-77.
60. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59: 478-90.
61. Penkler, L., Müller, R.H., Runge, S., Ravelli, V. Pharmaceutical cyclosporine formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. WO9956733 (1999).
62. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327: 153-9.
63. Tabatt K, Kneuer C, Sameti M, Olbrich C, Muller RH, Lehr CM, et al. Transfection with different colloidal systems: Comparison of solid lipid nanoparticles and liposomes. J Control Rel 2004; 97: 321-32.
64. Bondi ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: A review of the state of the art. Expert Opin. Drug Deliv 2010; 7(1): 7-18.
65. Gasco, M.R. Lipid nanoparticles as vehicles for nucleic acids, process for their preparation ans use. WO2005120469 (2005).
66. Kneuer, C., Lehr, C-M., Olbrich, C., Mler, R.H. Transfection complexes (Transoplex) having a reduced toxicity, a higher physical stability, and a higher transfection efficiency, and a method for the production thereof. WO02051446 (2002).
67. Gascon A.R., Solinis M.A., del Pozo-Rodriguez A., Delgado D., Pedraz J.L. Lipid nanoparticles for gene therapy. WO2011015701 (2011).
68. Obeidat WM, Schwabe K, Müller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2010; 76: 56-67.
69. Keck, C. Compositions containing lipid microor nanoparticles for the enhancement of the dermal action of solid particles. WO2010051918 (2010).
70. Padois, K., Pirot, F., Falson, F. Solid lipid nanoparticles encapsulating minoxidil and aqueous suspension containing same. WO2010112749 (2010).
71. Dahms, G., Jung, A., Seidel, H. Compositions for targetted release of fragrances and aromas. WO2004098555 (2004).
72. Müller, R.H., Wissing, S.A., Mäder, K. UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing the natural skin barrier. WO0103652 (1999).
73. Farboud ES, Nasrollahi SA, Tabbakhi Z. Novel formulation and evaluation of a Q10-loaded solid lipid nanoparticle cream: In vitro and in vivo studies. Int J Nanomed 2011; 6: 611-7.
74. Müller R.H., Grubhofer N., Olbrich C. Adjuvant which is optimized with regard to stability and biocompatibility (SBA) and which is improved for increasing the humoral and cellular immune responses. WO0071077 (2000).
75. Müller, R.H., Grubhofer, N., Olbrich, C. Stability, biocompatibility optimized adjuvant (SBA) for enhancing humoral and cellular immune response. WO0071154 (2000).
76. Kim J-K, Park J-S, Kim C-K (2010). Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm 2010; 38: 209-15.
77. Ghaffari S, Varshosaz J, Saadat A, Atyabi F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. Int J Nanomed 2011; 6: 35-43.
78. Xie S, Zhu L, Dong Z, Wang Y, Wang X, Zhou W-Z. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomed 2011; 6: 547-555.
79. Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: Application to topical delivery of tacroilimus. Eur J Pharm Biopharm 2011; Doi: 10.1016/j.ejpb.2011.02.016.
80. Aditya NP, Patankar S, Madhusudhan B, Murthy RSR, Souto EB. Arthemeter-loaded lipid nanoparticles produced by modified thinfilm hydration: Pharmacokinetics, toxicological and in vivo antimalarial activity. Eur J Pharm Sci 2010; 40: 448-55.
81. Fang J-Y, Fang C-L, Liu C-H, SU Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70: 633-40.
82. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-13.
83. Attama AA, Weber C, Müller-Goymann CC. Assessment of drug permeation from SLN formulated with a novel structured lipid matrix through artificial skin construct bio-engineered from HDF and HaCaT cell lines. J Drug Deliv Sci Technol 2008; 18(3): 181-8.
84. Attama AA, Reichl S, Müller-Goymann CC. Sustained release and permeation of timolol from surface modified solid lipid nanoparticles through bio-engineered human cornea. Curr Eye Res 2009; 34(8): 698-705.
85. Muller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6): 522-30.
86. Souto EB, Müller RH. In: Wiechers J, Kozlowski A, Eds. Science and Applications of Skin Delivery Systems. Chicago: Allured Publishing 2008: 227-50.
87. Wissing S, Lippacher A, Muller R. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 2001; 52(5): 313-24.
88. Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43: 174-9.
89. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: Characterization. Eur J Pharm Biopharm 2007; 67: 48-57.
90. Lee, S-W. Solid lipid nanoparticles for drug delivery, a production method therefor, and injectable preparation comprising the nanoparticles. WO2009102121 (2009).
91. Schwarz, J., Weisspapir, M. Colloidal solid lipid vehicle for pharmaceutical use. WO2006102768 (2006).
92. Ivri, Y. Solid lipid nanoparticles: Intracochlear drug delivery to the central nervous system. WO2011019954 (2011).
93. Wu, N., Keller, B.C. Lipid drug conjugates for drug delivery. WO2010107487 (2010).
94. Bondi, M.L., Giammona, G., Craparo, E.F., Drago, F. Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles. WO2008000448 (2008).
95. Westersen, K., Siekmann, B. Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof. WO9420072 (1994).
96. Gasco M.R. Method for producing solid lipid microspheres having a narrow size distribution. US5250236 (1993).
97. Gasco, M.R. Formulations of active principles incorporated in SLNs suitable for transdermal administration. WO2008041116 (2008).
98. Gasco, M.R. Use of solid lipid nanoparticles comprising cholesteryl propionate and/or cholesteryl butyrate. WO2006128888 (2006).
99. Gasco, M.R., Gasco, P., Bernareggi, A. Nanoparticle formulations of platinum compounds. WO2005092298 (2005).
100. Gasco, M.R., Zara, G.P., Saettone, M.F. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. WO2004039351 (2004).
101. Gasco, M.R. Microparticles for drug delivery across mucosa and the blood-brain barrier. WO9927918 (1999).